Bicycle Therapeutics PLCNASDAQ:BCYC
- LAST PRICE20.3600
- TODAY'S CHANGE (%)0.4100 (2.0551%)
- Bid / Lots20.3200/ 3
- Ask / Lots20.4000/ 1
- Open / Previous Close20.2800 / 19.9500
- Day Range
- 52 Week Range
- Volume88,017
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BCYC |
|---|---|---|
| 09:32 ET | 2925 | 20.82 |
| 09:33 ET | 20249 | 21.23 |
| 09:35 ET | 400 | 20.56 |
| 09:37 ET | 400 | 20.55 |
| 09:39 ET | 1992 | 20.465 |
| 09:42 ET | 600 | 20.15 |
| 09:44 ET | 531 | 20.263336 |
| 09:48 ET | 400 | 20.3349 |
| 09:51 ET | 709 | 20.39 |
| 09:53 ET | 100 | 20.36 |
| 09:55 ET | 1132 | 20.345 |
| 09:57 ET | 300 | 20.305 |
| 10:02 ET | 300 | 20.06 |
| 10:08 ET | 300 | 20.23 |
| 10:09 ET | 2283 | 20.25 |
| 10:15 ET | 100 | 20.205 |
| 10:20 ET | 300 | 20.1 |
| 10:24 ET | 100 | 20.195 |
| 10:26 ET | 617 | 20 |
| 10:27 ET | 1920 | 19.965 |
| 10:29 ET | 400 | 19.965 |
| 10:31 ET | 1641 | 20.07 |
| 10:33 ET | 500 | 20.1 |
| 10:38 ET | 100 | 19.975 |
| 10:40 ET | 729 | 19.955 |
| 10:45 ET | 100 | 19.99 |
| 10:51 ET | 100 | 19.995 |
| 10:56 ET | 874 | 19.935 |
| 10:58 ET | 1300 | 19.935 |
| 11:00 ET | 1386 | 19.94 |
| 11:02 ET | 300 | 19.93 |
| 11:03 ET | 1000 | 20.005 |
| 11:05 ET | 800 | 20.09 |
| 11:07 ET | 460 | 20.01 |
| 11:14 ET | 500 | 19.955 |
| 11:16 ET | 900 | 19.945 |
| 11:18 ET | 400 | 19.965 |
| 11:20 ET | 600 | 20.03 |
| 11:21 ET | 100 | 20.125 |
| 11:27 ET | 100 | 20.125 |
| 11:30 ET | 182 | 20.02 |
| 11:32 ET | 100 | 20.125 |
| 11:34 ET | 100 | 20.125 |
| 11:45 ET | 1600 | 20.325 |
| 11:48 ET | 127 | 20.325 |
| 11:50 ET | 100 | 20.325 |
| 11:52 ET | 100 | 20.37 |
| 11:56 ET | 100 | 20.39 |
| 11:57 ET | 100 | 20.38 |
| 11:59 ET | 2756 | 20.425 |
| 12:01 ET | 1255 | 20.285 |
| 12:08 ET | 400 | 20.3 |
| 12:10 ET | 3000 | 20.3 |
| 12:12 ET | 4777 | 20.3 |
| 12:14 ET | 779 | 20.355 |
| 12:15 ET | 4526 | 20.34 |
| 12:17 ET | 100 | 20.36 |
Yesterday
Nov 12, 2024
Bicycle Therapeutics to Participate in the Jefferies London Healthcare Conference, from 7:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
7:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
Nov 8, 2024
DJ Bicycle Therapeutics Initiated at Equal-Weight by Stephens & Co., from 7:24AM ET on Friday Nov 08, 2024 by Dow Jones
7:24AM ET on Friday Nov 08, 2024 by Dow Jones
Nov 1, 2024
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 4:05PM ET on Friday Nov 01, 2024 by Dow Jones
4:05PM ET on Friday Nov 01, 2024 by Dow JonesDJ Bicycle Therapeutics Price Target Maintained With a $35.00/Share by RBC Capital, from 1:01PM ET on Friday Nov 01, 2024 by Dow Jones
1:01PM ET on Friday Nov 01, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Bicycle Therapeutics PLC | 1.4B | -6.2x | --- |
Intellia Therapeutics Inc | 1.5B | -2.7x | --- |
Praxis Precision Medicines Inc | 1.4B | -7.7x | --- |
Day One Biopharmaceuticals Inc | 1.4B | -13.2x | --- |
Syndax Pharmaceuticals Inc | 1.4B | -4.6x | --- |
ARS Pharmaceuticals Inc | 1.4B | -27.8x | --- |
Company Information
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating BT8009, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology. Its product candidates also include BT1718 and BT7455.
Contact Information
- Headquarters
- Blocks A & B, Portway Building, Granta PCAMBRIDGE, United Kingdom CB21 6GS
- Phone
- 122-326-1503
- Fax
- ---
Executives
- Non-Executive Chairman of the Board
- Pierre Legault
- Chief Executive Officer, Executive Director
- Kevin Lee
- Chief Financial Officer, Principal Financial Officer
- Alethia Young
- Chief Operating Officer
- Alistair Milnes
- Chief Technology Officer
- Michael Skynner
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.4B |
|---|---|
Revenue (TTM) | $36.9M |
Shares Outstanding | 69.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.86 |
EPS | $-3.28 |
Book Value | $8.74 |
P/E Ratio | -6.2x |
Price/Sales (TTM) | 38.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -534.98% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
